Prospective, single-blind, placebo-controlled, three-treatment, three-period, adaptive multi-centre Phase IIa (proof-of-concept) trial to investigate the efficacy, safety, and tolerability of Ketamine HCl PR tablets in patients with chronic non-malignant neuropathic pain
Latest Information Update: 21 Jun 2018
At a glance
- Drugs Ketamine (Primary)
- Indications Neuropathic pain
- Focus Proof of concept; Therapeutic Use
- Sponsors Develco Pharma Schweiz
Most Recent Events
- 21 Jun 2018 New trial record